Alexander Zaslavsky
Overview
Explore the profile of Alexander Zaslavsky including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
39
Citations
1494
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Shakya R, Suraneni P, Zaslavsky A, Rahi A, Magdongon C, Gajjela R, et al.
bioRxiv
. 2024 Oct;
PMID: 39464080
Castration-resistant prostate cancer (CRPC) progresses despite androgen deprivation therapy, as cancer cells adapt to grow without testosterone, becoming more aggressive and prone to metastasis. CRPC biology complicates the development of...
2.
Aris M, Sood A, Zaslavsky A
Front Cell Dev Biol
. 2024 Feb;
12:1373463.
PMID: 38415273
No abstract available.
3.
Min J, Zaslavsky A, Fedele G, McLaughlin S, Reczek E, De Raedt T, et al.
Nat Med
. 2024 Feb;
30(6):1790.
PMID: 38383797
No abstract available.
4.
Charles C, Lloyd S, Piyarathna D, Gohlke J, Rasaily U, Putluri V, et al.
Am J Clin Exp Urol
. 2023 Dec;
11(6):594-612.
PMID: 38148936
Prostate cancer (PCa) is the second most common cancer and constitutes about 14.7% of total cancer cases. PCa is highly prevalent and more aggressive in African-American (AA) men than in...
5.
Stensland K, Caram M, Herr D, Burns J, Sparks J, Elliott D, et al.
Urology
. 2023 Nov;
184:135-141.
PMID: 37951360
Objective: To examine survival and disease control outcomes, including metastasis-related survival outcomes, in a large contemporary cohort of patients undergoing radical prostatectomy for localized prostate cancer. Methods: We conducted a...
6.
Herr D, Elliott D, Duchesne G, Stensland K, Caram M, Chapman C, et al.
Cancer
. 2023 Jun;
129(20):3326-3333.
PMID: 37389814
Purpose: Accurate information regarding real-world outcomes after contemporary radiation therapy for localized prostate cancer is important for shared decision-making. Clinically relevant end points at 10 years among men treated within...
7.
Stensland K, Devasia T, Caram M, Chapman C, Zaslavsky A, Morgan T, et al.
JNCI Cancer Spectr
. 2022 May;
6(3).
PMID: 35616109
Background: The Timing Of Androgen Deprivation (TOAD) trial found an overall survival benefit for immediate vs delayed androgen deprivation therapy (ADT) for prostate-specific antigen (PSA)-relapsed or noncurable prostate cancer. However,...
8.
Cristoloveanu S, Lacord J, Martinie S, Navarro C, Gamiz F, Wan J, et al.
Micromachines (Basel)
. 2021 Dec;
12(12).
PMID: 34945390
This paper reviews the recently-developed class of band-modulation devices, born from the recent progress in fully-depleted silicon-on-insulator (FD-SOI) and other ultrathin-body technologies, which have enabled the concept of gate-controlled electrostatic...
9.
Nallandhighal S, Vince R, Karim R, Groves S, Stangl-Kremser J, Russell C, et al.
Eur Urol Oncol
. 2021 Nov;
5(1):92-99.
PMID: 34840106
Background: There is an ongoing need to develop prognostic biomarkers to improve the management of clear cell renal cell carcinoma (ccRCC). Objective: To leverage enriched pathways in ccRCC to improve...
10.
Stangl-Kremser J, Rasul S, Tosoian J, Salami S, Zaslavsky A, Udager A, et al.
Eur Urol Open Sci
. 2021 Aug;
30:63-66.
PMID: 34337549
Patient Summary: Treatment with a radioactive binding molecule called [Lu]-PSMA-617 for men with prostate cancer resistant to castration (CRPC) is showing promise. We investigated the association between the presence of...